Literature DB >> 11465953

Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele.

T O Fedczyna1, J Lutz, L M Pachman.   

Abstract

Juvenile dermatomyositis (JDM) is the most common pediatric inflammatory myopathy. In patients with JDM, the A --> G polymorphism in the tumor necrosis factor alpha (TNFalpha)-308 promoter region (TNFalpha-308A) is associated with prolonged disease course and increased production of TNFalpha by peripheral blood mononuclear cells (Arthritis Rheum. 43, 2368-2377, 2000). Magnetic resonance imaging directed biopsies from 21 white children with untreated JDM were evaluated for TNFalpha expression. Using monoclonal antibody to TNFalpha, fresh frozen sections were processed by the standard immunohistochemical technique. We investigated the association among the expression of TNFalpha by muscle fibers, disease activity, duration of untreated disease, and the TNFalpha-308 polymorphism. Untreated children with JDM who had the TNFalpha-308A allele had an increased number of TNFalpha stained muscle fibers than children with the TNFalpha-308G allele (P = 0.001). There was no association with disease activity or duration of untreated disease. We speculate that muscle fiber production of TNFalpha provides a microenvironment in which TNFalpha acts synergistically with other mediators to prolong muscle fiber damage. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465953     DOI: 10.1006/clim.2001.5063

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  14 in total

Review 1.  Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis.

Authors:  Lauren M Pachman; Adele L Boskey
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

2.  The inflammatory milieu in idiopathic inflammatory myositis.

Authors:  Ann M Reed; Floranne Ernste
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 3.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

4.  A randomized, pilot trial of etanercept in dermatomyositis.

Authors: 
Journal:  Ann Neurol       Date:  2011-06-17       Impact factor: 10.422

5.  Apoptosis in the skeletal muscle of untreated children with juvenile dermatomyositis: impact of duration of untreated disease.

Authors:  Yongdong Zhao; Tamara O Fedczyna; Violet McVicker; Jan Caliendo; Honglin Li; Lauren M Pachman
Journal:  Clin Immunol       Date:  2007-08-20       Impact factor: 3.969

6.  Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis.

Authors:  Gulnara Mamyrova; Terrance P O'Hanlon; Laura Sillers; Karen Malley; Laura James-Newton; Christina G Parks; Glinda S Cooper; Janardan P Pandey; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2008-12

7.  Juvenile dermatomyositis calcifications selectively displayed markers of bone formation.

Authors:  Annette L Urganus; Yong-Dong Zhao; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2009-04-15

Review 8.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

Review 9.  The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy.

Authors:  Boel De Paepe; Kim K Creus; Jan L De Bleecker
Journal:  Clin Dev Immunol       Date:  2011-10-23

10.  Associations between TNF-α-308A/G polymorphism and susceptibility with dermatomyositis: a meta-analysis.

Authors:  Si Chen; Qian Wang; Ziyan Wu; Qingjun Wu; Ping Li; Yuan Li; Jing Li; Chuiwen Deng; Chanyuan Wu; Lei Gao; Fengchun Zhang; Yongzhe Li
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.